PubRank

Rolf A Brekken

Author PubWeight™ 107.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009 3.96
2 A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. J Am Chem Soc 2008 2.47
3 Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002 2.41
4 Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009 2.39
5 Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A 2012 2.24
6 Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circ Res 2007 2.22
7 Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007 2.19
8 Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003 2.08
9 Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 2010 1.90
10 Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 2008 1.61
11 Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 2008 1.61
12 Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 2013 1.60
13 Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005 1.57
14 Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2004 1.54
15 Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 2009 1.53
16 Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009 1.53
17 Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010 1.48
18 The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2011 1.41
19 Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 2013 1.41
20 SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal 2009 1.41
21 Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009 1.40
22 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 2013 1.39
23 A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 2013 1.37
24 Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest 2006 1.36
25 Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 2007 1.31
26 Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004 1.31
27 Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 2006 1.31
28 RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov 2013 1.25
29 SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 2004 1.24
30 Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 2005 1.23
31 BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther 2013 1.19
32 Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol 2005 1.19
33 Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 2007 1.18
34 SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner. Cancer Res 2011 1.13
35 r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. PLoS One 2010 1.13
36 Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 2007 1.11
37 Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. J Cell Commun Signal 2009 1.11
38 Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) 2008 1.08
39 Lack of "immunological fitness" during fasting in metabolically challenged animals. J Lipid Res 2012 1.08
40 MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc 2010 1.08
41 Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther 2011 1.06
42 Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011 1.06
43 K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res 2009 1.06
44 Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium. PLoS One 2011 1.06
45 TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res 2012 1.06
46 Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res 2008 1.05
47 Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery 2006 1.05
48 Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS. Dis Model Mech 2010 1.04
49 The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. Int J Cancer 2007 1.03
50 The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. Bioorg Med Chem Lett 2008 1.03
51 SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity. J Cell Biol 2011 1.02
52 Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Exp Biol Med (Maywood) 2010 1.01
53 PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther 2013 1.01
54 The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 2011 1.01
55 SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol 2011 1.00
56 Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006 0.99
57 Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem 2004 0.99
58 Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation. PLoS One 2012 0.98
59 Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest 2013 0.97
60 Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice. Cancer 2010 0.96
61 Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 2013 0.96
62 GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 2010 0.94
63 Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. Ann Surg Oncol 2006 0.93
64 SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. J Histochem Cytochem 2005 0.93
65 The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008 0.92
66 Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res 2012 0.92
67 Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature. PLoS One 2013 0.91
68 Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer 2011 0.90
69 Recruitment and retention: factors that affect pericyte migration. Cell Mol Life Sci 2013 0.90
70 Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. Dis Model Mech 2010 0.90
71 Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. J Clin Invest 2014 0.90
72 Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts. Mol Cancer Ther 2012 0.89
73 Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. Nephrol Dial Transplant 2010 0.89
74 SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. J Invest Dermatol 2011 0.88
75 Role of SPARC in bone remodeling and cancer-related bone metastasis. J Cell Biochem 2014 0.87
76 The acellular fraction of stored platelets promotes tumor cell invasion. J Surg Res 2008 0.87
77 Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes 2013 0.85
78 Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis 2012 0.85
79 VEGF and pleiotrophin modulate the immune profile of breast cancer. Cancers (Basel) 2010 0.84
80 Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. J Cell Biochem 2003 0.84
81 Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) 2010 0.84
82 A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site. Bioorg Med Chem 2008 0.83
83 VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther 2013 0.83
84 Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am J Obstet Gynecol 2008 0.83
85 Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol 2010 0.82
86 LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest 2015 0.82
87 The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy. Curr Drug Targets 2016 0.82
88 Clonal analysis reveals a common progenitor for endothelial, myeloid, and lymphoid precursors in umbilical cord blood. Circ Res 2010 0.82
89 Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer? Cancer Discov 2012 0.76
90 Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. Anticancer Res 2011 0.75